Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Key Points

• Armata Pharmaceuticals beat quarterly expectations: The clinical-stage biotech reported an adjusted loss of $0.27 per share, $0.21 better than analysts’ expected loss of $0.48. Revenue reached $2.51 million, well above the $0.40 million consensus estimate.
• Shares rose 1.4% to $4.31 following the results, though the stock remains below its 50-day and 200-day moving averages and has traded between $2.39 and $16.34 over the past year.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus and a $15 average price target. Armata is developing bacteriophage therapies targeting antibiotic-resistant infections, including those caused by Pseudomonas aeruginosa and Staphylococcus aureus.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.21, FiscalAI reports. The business had revenue of $2.51 million for the quarter, compared to analysts' expectations of $0.40 million.

Armata Pharmaceuticals Stock Up 1.4%

Shares of NYSEAMERICAN ARMP traded up $0.06 during mid-day trading on Wednesday, reaching $4.31. 126,433 shares of the company were exchanged, compared to its average volume of 92,798. Armata Pharmaceuticals has a 52 week low of $2.39 and a 52 week high of $16.34. The company's 50 day moving average price is $5.77 and its 200 day moving average price is $8.15. The stock has a market capitalization of $158.22 million, a PE ratio of -0.55 and a beta of 1.30.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in shares of Armata Pharmaceuticals during the 4th quarter valued at about $108,000. Millennium Management LLC purchased a new stake in Armata Pharmaceuticals in the fourth quarter worth approximately $164,000. OMERS ADMINISTRATION Corp bought a new position in Armata Pharmaceuticals during the fourth quarter valued at approximately $177,000. Goldman Sachs Group Inc. bought a new position in Armata Pharmaceuticals during the fourth quarter valued at approximately $284,000. Finally, State Street Corp raised its stake in shares of Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company's stock worth $319,000 after acquiring an additional 10,500 shares in the last quarter. Institutional investors own 3.57% of the company's stock.

Analyst Ratings Changes

Separately, Zacks Research upgraded Armata Pharmaceuticals to a "hold" rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.00.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source